17,084 reports of this reaction
7.3% of all Tecfidera reports
#1 most reported adverse reaction
FLUSHING is the #1 most commonly reported adverse reaction for Tecfidera, manufactured by Biogen Inc.. There are 17,084 FDA adverse event reports linking Tecfidera to FLUSHING. This represents approximately 7.3% of all 233,327 adverse event reports for this drug.
Patients taking Tecfidera who experience flushing should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FLUSHING is moderately reported among Tecfidera users, representing a notable but not dominant share of adverse events.
In addition to flushing, the following adverse reactions have been reported for Tecfidera:
The following drugs have also been linked to flushing in FDA adverse event reports:
FLUSHING has been reported as an adverse event in 17,084 FDA reports for Tecfidera. This does not prove causation, but indicates an association observed in post-market surveillance data.
FLUSHING accounts for approximately 7.3% of all adverse event reports for Tecfidera, making it one of the most commonly reported side effect.
If you experience flushing while taking Tecfidera, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.